LGALS9 and neoplasm: NK–tumor interactions included HLA-C/KIR2DL4, HLA-E/CD94 (KLD1), TIM3 (HAVCR2)/Galectin-9, CD96-PVR/Nectin1 and TIGIT-PVR/Nectin2 [126,127].